603259 药明康德
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入7,981,934-10.95%40,340,80739,354,77822,902,38516,535,431
减:营业总成本5,643,909-16.70%28,708,59129,800,81118,574,51613,928,304
    其中:营业成本4,938,382-8.34%23,728,80024,677,21714,592,25610,253,276
               财务费用(424,362)-392.93%(338,119)(247,968)84,082519,804
               资产减值损失6,595-183.76%(156,509)(175,951)(33,056)(62,642)
公允价值变动收益(84,012)-151.04%(37,809)770,079(93,387)52,271
投资收益(8,925)-105.03%233,849187,9491,356,269606,231
    其中:对联营企业和合营企业的投资收益34,144-191.05%(67,560)(46,271)(117,290)(90,752)
营业利润2,309,847-11.68%11,872,28610,652,2496,037,7253,389,485
利润总额2,297,394-11.94%11,831,99110,618,4766,015,6093,369,376
减:所得税费用338,541-19.98%2,131,7311,715,866879,662383,126
净利润1,958,853-10.38%9,700,2608,902,6115,135,9472,986,250
减:非控股权益16,643-5.85%93,51188,89838,79226,015
股东净利润1,942,211-10.42%9,606,7498,813,7135,097,1552,960,235

市场价值指针
每股收益 (元) *0.670-9.46%3.2703.0101.7501.060
每股派息 (元) *----0.9830.8930.5170.363
每股净资产 (元) *18.96813.76%18.57015.73713.02013.308
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容